Affiliation:
1. Peking Union Medical College Hospital
Abstract
Abstract
Background
The prognosis of high-grade LNETs patients was poor. Although previous studies have tried to explore molecular markers to stratify LNETs and to seek the therapeutic targets, there was little improvement in the treatment strategy and overall survival of high-grade LNET patients.
Materials and Methods
In our study, gene expression data and clinical features of LNETs patients were extracted from GSE30219 dataset, which was further divided into training cohort and validation cohort. Univariate cox regression analysis and LASSO method were used to construct a prognostic risk model. The predictive value of prognostic gene signature was evaluated by ROC curve analysis.
Results
An eight-gene signature predicting survival was constructed in training cohort and was further validated in validation cohort. This gene signature performed well in both early-stage and advanced-stage high-grade LNET patients. Moreover, multivariate cox regression analysis revealed that this gene signature was the only independent risk factor in high-grade LNET patients, while age, gender, pathological stage, T stage, N stage and M stage were not. GO analysis and KEGG pathway analysis of DEGs and GSEA analysis based on subgroups stratified by gene signature in high-grade LNET patients revealed the high activity of tumor cell division, proliferation and metabolization.
Conclusion
We identified a novel and reliable gene signature risk model for predicting prognosis in high-grade LNET patients, which could stratify high-risk LNETs patients and might provide new targets.
Publisher
Research Square Platform LLC
Reference43 articles.
1. Cancer statistics, 2020;Siegel RL;CA Cancer J Clin,2020
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018
3. Consensus on biomarkers for neuroendocrine tumour disease;Oberg K;Lancet Oncol,2015
4. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification;Travis WD;J Thorac Oncol,2015
5. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study;Fitzmaurice C;JAMA Oncol,2018